	Application No.	Applicant(s)
	10/783,415	MARCHETTI ET AL.
Notice of Allowability	Examiner	Art Unit
	MINH-TAM DAVIS	1642
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to interview of 12/14/05.		
2. The allowed claim(s) is/are <u>56-67, renumbered as 1-12</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority une a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 		
Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
• • • •		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	_	
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 12/09/05;02/19/04		
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
or brorogical injectial	9.	

Application/Control Number: 10/783,415

Art Unit: 1642

EXAMINER'S AMENDMENT/REASONS FOR ALLOWANCE

1) An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Susan Siegel on 12/14/05.

The application has been amended as follows:

In the claims:

Claim 65 was amended as follows:

"that specifically binds SEQ ID NO:4, or a fragment of SEQ ID NO:4 that deregulates mammary epithelial cellular growth" was deleted.

Claim 66 was amended as follows:

Claim 66 (amended). The kit of claim [[62]] 65, further comprising

a container comprising a second antibody that specifically binds the purified antibody of claim 56 that specifically binds SEQ ID NO:4 [[,]] or a fragment of SEQ ID NO:4 that deregulates mammary epithelial cellular growth.

wherein the second antibody comprises a label.

2) It is noted that the deposit requirement is not necessary for the cDNA encoding the polypeptide to which the claimed antibody binds of claim 64, because the cDNA required to practice the inventions of claim 64 is publicly available by virtue of the

Art Unit: 1642

fact that all requirements of 37 CFR 1.801-1.809 have been satisfied in US Patent No: 6,255,105.

3) The following is an examiner's statement of reasons for allowance:

The polypeptide of SEQ ID NO:4, to which the claimed antibody binds, is supported by a specific and substantial utility, in view that the polynucleotide encoding SEQ ID NO:4 is not detected in some tissue samples of human lung cancer, as compared to normal lung tissue, as shown in the northern blot in Figure 16 and on page 56, lines 14-15 of the specification, and further in view that since the encoding polynucleotide is not detected, one would have expected that the encoded polypeptide of SEQ ID NO:4 would not be detected.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JEFFREY SIEW can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/783,415

Art Unit: 1642

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS December 19, 2005

SUSAN UNGAR, PH.D. PRIMARY EXAMINE: